Conversely, given that S1P inhibitors are in trials for treatment of multiple sclerosis and inflammatory bowel disease, similar drugs could potentially be used to block S1P-dependent ILC2 trafficking and help treat patients that suffer from chronic type 2 autoimmunity like asthma or dermatitis [179,180]. This evidence concerns the gene MBTPS1 and multiple sclerosis.